Transfer News

BREAKING NEWS: Chelsea FC is said to have verbally agreed to secure the services of Bayer Leverkusen’s striker for the 2024/2025 season.

BREAKING NEWS: Chelsea FC is said to have verbally agreed to secure the services of Bayer Leverkusen’s striker for the 2024/2025 season.

Chelsea is actively seeking a new striker, as they have found Nicolas Jackson’s performance underwhelming. The Senegalese player has yet to make a significant impact at Stamford Bridge, prompting the club to look for a more reliable goal-scorer in the transfer market.

Their top target is Victor Osimhen, a highly regarded Nigerian forward. However, Chelsea faces stiff competition from Paris Saint-Germain (PSG), who view Osimhen as a potential replacement for Kylian Mbappe, should Mbappe move to Real Madrid.

Another player on Chelsea’s radar is Ivan Toney from Brentford. But signing Toney is complicated by interest from other Premier League giants like Arsenal and Manchester United, making the transfer far from straightforward.

Given these challenges, Chelsea may need to broaden their search. One emerging option is Victor Boniface, a promising striker currently playing for Bayer Leverkusen. Reports from BILD and transfer expert Christian Falk suggest that Chelsea is eyeing Boniface, who joined Leverkusen from Saint-Gilloise in 2023 for €16 million. His current contract runs until 2028, and he is now valued at around €40 million. However, Bayer Leverkusen is reluctant to sell him.

Boniface has demonstrated impressive form, scoring 16 goals and providing eight assists in just 23 games before suffering an adductor injury. This injury will keep him out for several months. Despite his talent, there are concerns about his injury history, including two ACL injuries earlier in his career.

If he can stay fit, the 23-year-old Boniface is considered one of Europe’s most promising young forwards. Chelsea’s pursuit of a new striker continues as they look to bolster their attacking options and find a player who can consistently deliver goals.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button